8-K: Quince Therapeutics Secures $11.5 Million in Private Placement, Bolstering Capital with Equity and Warrants

Quince Therapeutics, Inc. has announced a private placement raising approximately $11.5 million through the sale of common stock, pre-funded warrants, and common warrants to institutional investors and company management.

Summary

• Quince Therapeutics, Inc. entered into a Securities Purchase Agreement on June 12, 2025, for a private placement with institutional investors and certain members of its management.
• The company will issue and sell 6,671,928 shares of common stock, pre-funded warrants to purchase up to 2,000,000 shares, and accompanying common warrants to purchase up to 8,671,928 shares.
• The aggregate gross proceeds from this private placement are approximately $11.5 million, excluding potential future proceeds of up to $10.4 million from the cash exercise of the common warrants.
• The combined purchase price for each share and accompanying common warrant is $1.325, while each pre-funded warrant and accompanying common warrant is priced at $1.324.
• Common warrants are exercisable at $1.20 per share and expire on the five-year anniversary of their issuance date.
• Pre-funded warrants are immediately exercisable at a nominal price of $0.001 per share and do not expire until fully exercised.
• A beneficial ownership limitation prevents holders from exercising warrants if it would result in ownership exceeding 4.99% (or 9.99% at holder's option, adjustable up to 19.99%) of the company's outstanding common stock.
• The company has committed to filing a registration statement for the resale of the shares and warrant shares no later than 120 days following June 12, 2025, and to use reasonable best efforts for its effectiveness within 30 days (or 75 days if reviewed by the SEC).
• Management, including CEO Dirk Thye ($200,000), COO Brendan Hannah ($50,000), and President Charles Ryan ($10,000), participated in the private placement.
• The securities were offered and sold in a private placement under Section 4(a)(2) of the Securities Act and Regulation D, and have not been registered.

Sentiment

Score: 6

Explanation: The capital raise provides essential funding and shows management's commitment, which is positive. However, the significant potential for dilution from the warrants and the associated risks of registration delays introduce some caution, leading to a moderately positive sentiment.

Positives

• The private placement provides Quince Therapeutics with approximately $11.5 million in immediate gross proceeds, enhancing its capital position.
• The potential for an additional $10.4 million in gross proceeds from the cash exercise of common warrants offers future funding potential.
• Participation by key management figures (CEO, COO, President) in the private placement signals confidence in the company's future.
• The company has committed to registering the resale of the shares and warrant shares, providing liquidity for investors.

Negatives

• The issuance of a significant number of common shares and warrants (up to 8,671,928 common warrants and 2,000,000 pre-funded warrants) could lead to substantial dilution for existing shareholders upon exercise.
• The low exercise price of $0.001 for pre-funded warrants means they are deeply in-the-money, making their exercise highly probable and contributing to immediate dilution.
• The company is subject to liquidated damages if it fails to meet registration statement filing and effectiveness deadlines, indicating a potential financial penalty for delays.

Risks

• **Dilution Risk**: The exercise of common warrants and pre-funded warrants will significantly increase the number of outstanding common shares, potentially diluting the ownership and voting power of current shareholders.
• **Registration Risk**: Failure to timely file or achieve effectiveness of the resale registration statement could result in liquidated damages payable by the company, impacting its financial resources.
• **Market Overhang**: The future resale of a large number of shares underlying the warrants, once registered, could create downward pressure on the company's stock price.
• **Beneficial Ownership Limitations**: Restrictions on beneficial ownership (4.99% or 9.99%, adjustable to 19.99%) may limit the immediate exercise of warrants by large investors, but these can be adjusted, potentially leading to future large-scale exercises.
• **Cashless Exercise**: The option for cashless exercise of warrants means the company may not receive the full cash proceeds from warrant exercises if certain registration conditions are not met, impacting its liquidity.

Future Outlook

Quince Therapeutics is committed to filing a registration statement for the resale of the newly issued shares and warrant shares within 120 days and aims for its effectiveness promptly thereafter. The company also plans to seek stockholder approval for the warrant issuance within 90 days of the closing date, with subsequent meetings every 90 days if initial approval is not obtained. There is a 60-day restriction on certain subsequent equity sales following the stockholder approval date, with specific exceptions.

Management Comments

• Dirk Thye, Chief Executive Officer, Chief Medical Officer, and a member of the board of directors, purchased Shares and Common Warrants for an aggregate purchase price of $200,000.
• Brendan Hannah, Chief Operating Officer, Chief Business Officer, and Chief Compliance Officer, purchased Shares and Common Warrants for an aggregate purchase price of $50,000.
• Charles Ryan, President, purchased Shares and Common Warrants for an aggregate purchase price of $10,000.

Industry Context

This private placement, involving a mix of common stock and warrants, is a common financing strategy for biotechnology companies like Quince Therapeutics. Such capital raises are crucial for funding ongoing research and development, clinical trials, and general corporate purposes in the capital-intensive biotech industry. The participation of institutional investors and company management reflects a typical funding pattern for early to mid-stage biotech firms seeking to extend their cash runway.

Corporate Governance

Related Party Transactions

• Dirk Thye, the current Chief Executive Officer, Chief Medical Officer, and a member of the board of directors, purchased Shares and Common Warrants for an aggregate purchase price of $200,000.
• Brendan Hannah, the current Chief Operating Officer, Chief Business Officer, and Chief Compliance Officer, purchased Shares and Common Warrants for an aggregate purchase price of $50,000.
• Charles Ryan, the current President, purchased Shares and Common Warrants for an aggregate purchase price of $10,000.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from the exercise of warrants, but the capital raise provides financial stability and runway for the company's operations. The requirement for stockholder approval for warrant issuance provides a mechanism for shareholder input.
• **Investors (Purchasers in Private Placement)**: Gain new equity and warrant positions with registration rights, offering a path to liquidity. Management's participation may signal alignment of interests.
• **Employees**: Enhanced financial stability may support continued operations and job security, potentially impacting morale and retention.
• **Creditors**: Improved liquidity and capital position may reduce financial risk, potentially enhancing the company's creditworthiness.
• **Customers/Partners**: A more stable financial position can support ongoing product development and commercialization efforts, potentially benefiting future customers and partners.

Next Steps

• The Company must file a Current Report on Form 8-K disclosing the material terms of the transactions by 9:00 a.m. New York City time on the first business day following June 12, 2025.
• The Company is required to file an initial Registration Statement for the resale of all Registrable Securities no later than the 120th calendar day following June 12, 2025.
• The Company must use reasonable best efforts to have the initial Registration Statement declared effective by the SEC no later than the earlier of the 30th calendar day following the Filing Deadline (or 75th day if SEC reviews) and the fifth business day after SEC notification of no review.
• The Company must hold an annual or special meeting of stockholders on or prior to the 90th day following the Closing Date to obtain Stockholder Approval for the issuance of the Warrants and Common Warrant Shares.
• If Stockholder Approval is not obtained at the first meeting, the Company must call a meeting every 90 days thereafter to seek approval until it is received or the Common Warrants are no longer outstanding.
• The Company must maintain the listing and trading of its Common Stock on the Nasdaq Global Select Market and comply with all Nasdaq listing requirements.

Key Dates

Recommendation

Keywords

Quince Therapeutics, QNCX, Private Placement, Equity Financing, Common Stock, Warrants, Pre-Funded Warrants, Capital Raise, SEC Filing, Nasdaq, Dilution, Registration Rights, Biotechnology, Pharmaceuticals